SARS-CoV-2 mRNA Vaccination and Graves’ Disease: a report of 12 cases and review of the literature

Ying Jie Chee¹, Huiling Liew¹, Wai Han Hoi², Yingshan Lee¹, Brenda Lim¹, Han Xin Chin¹, Ray Tian Rui Lai¹, Yunqing Koh¹, Michelle Tham¹, Cherng Jye Seow¹, Zhi Han Quek¹, Abel Weiliang Chen¹, Timothy Peng Lim Quek¹, Alvin Wai Kit Tan¹, Rinkoo Dalan¹,².

¹ Department of Endocrinology, Tan Tock Seng Hospital
² Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore

Corresponding Author:
Rinkoo Dalan
Department of Endocrinology
Tan Tock Seng Hospital
Lee Kong Chian School of Medicine
11 Jalan Tan Tock Seng
Singapore 308433
Email: Rinkoo_dalan@ttsh.com.sg
Phone no: 65-63571000
Disclosure summary: All authors state that they have no conflict of interest with regards to this manuscript.
Abstract

Context and objective:
Thyroid autoimmunity has been reported to be associated with SARS-CoV-2 and the SARS-CoV-2 vaccination recently. We report a series of patients who presented with new onset or relapse of Graves’ disease related hyperthyroidism shortly after receiving the SARS-CoV-2 mRNA vaccine at a single tertiary institution in Singapore.

Methods and results:
We describe 12 patients who developed hyperthyroidism within a relatively short interval (median onset of 17 (range: 5 - 63) days) after receiving the SARS-CoV-2 mRNA vaccine. The majority were females (11/12) with median age of 35.5 (range: 22-74) years. Six patients had new onset hyperthyroidism, while the other six had relapse of previously well-controlled Graves’ disease. TSH Receptor antibody concentrations ranged from 2.4-32 IU/L. Majority of the patients were able to go for the second dose of the vaccine without any further exacerbations. Literature review revealed 21 other similar cases reported from across the world.

Conclusion:
Our case series provide insight into the characteristics of individuals in whom Graves’ disease was triggered by the SARS-CoV-2 vaccination. Clinicians need to be vigilant of precipitation or exacerbation of autoimmune thyroid disorders in predisposed individuals after exposure to the SARS-CoV-2 vaccination. Further epidemiological and mechanistic
studies are required to elucidate the possible associations between the SARS-CoV-2 vaccines and the development of thyroid autoimmunity.

**Keywords:** SARS-CoV-2 vaccine, Graves’ disease, hyperthyroidism
Introduction:

The SARS-CoV-2 virus pandemic has affected more than 275 million people worldwide (1). Globally, vaccination efforts are being ramped up to reduce mortality and transmission of the virus. To date, there are nine vaccines approved by the World Health Organization (2), which can be classified broadly based on the types of viral components (whole virus versus individual viral component) used in the production (3). The RNA-based vaccines (Pfizer/BioNTech BNT162b2 and Moderna mRNA-1273) are two widely administered vaccines.

The global prevalence of hyperthyroidism ranges from 0.1% to 2.5% in iodine sufficient countries, of which approximately 70-80% are Graves’ disease. In iodine deficient regions, the prevalence of hyperthyroidism ranges from 0.4 – 2.9%. Graves’ disease accounts for 50% of these cases (4). New onset or relapse of Graves’ disease is reported to occur within days (up to 38 days) after receiving the first or second dose of SARS-CoV-2 vaccines, predominantly the RNA-based ones (5-17).

Singapore is an iodine sufficient, island city-state in maritime Southeast Asia. The population of Singapore comprises of approximately 5.4 million people in three ethnic groups - Chinese, Malays and Indians (18). The country’s vaccination drive against COVID-19 started in January 2021 and more than 90% of the eligible population have completed the full regimen (19). Majority of the population received the RNA-based vaccines.
We describe a case series of 12 patients with new onset or relapsed Graves’ disease related hyperthyroidism post vaccination, presenting to a single tertiary Endocrinology clinic in Singapore.

**Case Series Description:**

We included all consecutive patients who presented with new onset or exacerbation of hyperthyroidism to our center with a temporal sequence to the vaccine between January to December 2021. All the participants signed an informed consent. The study was approved by our institutional review board (DSRB Ref: 2021/00960).

Twelve patients presented with Graves’ hyperthyroidism after they received the SARS-CoV-2 mRNA vaccines. Six patients had new onset symptoms, while the other six had relapse of previously well-controlled condition. None of the patients were known to have previous SARS-CoV-2 infection. The patients’ characteristics, laboratory results and progress are summarized in Table 1. There were 11 females: 9 Chinese and 3 non-Chinese (1 Malay and 2 Filipinos). One patient was a smoker. Five patients had a family history of thyroid disorders. Their median age was 35.5 (range: 22-74 years). All patients had a palpable non-tender diffuse goiter and 3 patients had signs and symptoms suggestive of mild to moderate thyroid eye disease. The overall median time to onset of hyperthyroid symptoms was 17 (IQR 8 – 27) days. Five patients developed clinical and/or biochemical hyperthyroidism after receiving the first dose of the SARS-CoV-2 mRNA vaccine with a median onset of 7 (IQR 5 – 21) days. The other 7 patients developed hyperthyroidism only after the second dose of the SARS-CoV-2 vaccine, with a median time of symptom onset of 21 (IQR 11 – 31) days after
the second dose. At initial diagnosis, the median free thyroxine (FT4) concentration [Chemiluminescent immunoassay; Beckman Coulter Dxl-800] was 49.5 pmol/L (IQR 24.5 – 69) (RI: 8-16). Free triiodothyronine (FT3) [Chemiluminescent immunoassay; Beckman Coulter Dxl-800] was performed in 4/12 with concentrations ranging from 6.3 pmol/L to more than 40 pmol/L (RI: 3.5 – 6.0). Thyroid stimulating hormone (TSH) [Chemiluminescent immunoassay; Beckman Coulter Dxl-800] was suppressed to <0.01 mIU/L in 6/12 and was close to 0.01 mIU/L in others. The median thyroid stimulating hormone receptor antibody (TRAb) [Eurommune Anti-TSHReceptor (TRAb) Fast ELISA, RRID:SCR_021945] concentration was 6.2 IU/L (Range 2.4-32) (RI: < 1) at diagnosis. For majority of the patients who relapsed, there was a clear increase in free T4 and suppression of TSH shortly after receiving the vaccine.

The five patients (Patients 1, 2, 4, 7 and 12) who developed hyperthyroidism after the first dose were treated with carbimazole as per usual clinical practice in our institution. Patients 1, 2, 4 and 12 did not experience exacerbation of hyperthyroidism clinically and biochemically after the second dose (Table 1). No adjustments to the anti-thyroid medication or beta-blockade doses were required after the second dose. Patient 7 already developed hyperthyroid symptoms 21 days after receiving the first dose of vaccine but proceeded with the second dose before finally presenting to his primary endocrinologist. Nine patients achieved normal FT4 within a median time of 42 (IQR 31 – 58) days.
Literature Review:

A literature review was performed in PubMed, google scholar using keywords thyroid, hyperthyroidism, Graves’ disease, thyroiditis, COVID-19, or SARS-CoV-2 vaccination. We found 21 other cases of Graves’ disease (5-17) (Table 2) occurring shortly after the SARS-CoV-2 vaccination.

Similar to our case series and background epidemiology of Graves’ disease (20), 13/21 cases were females in all age groups. Majority of cases presented after mRNA vaccines (12/21), while the other 9 cases presented after receiving vector-based vaccines. Sixteen developed new onset hyperthyroidism, while 3 developed worsening of known Graves’ hyperthyroidism. There was one interesting presentation of a patient who converted to hypothyroidism from hyperthyroidism after vaccination (6) and another individual had newly diagnosed Graves’ disease with concurrent subacute thyroiditis (14). Among these cases, 9 developed symptoms after the first dose, 7 after the second dose, 4 after a dose (first or second dose was not specified) and 1 after receiving a vector-based booster dose (this patient had received inactivated whole virus vaccine 3 months prior). There was paucity of follow-up clinical and biochemical data for majority of the patients, and there was insufficient information on whether those who developed new-onset or relapsed Graves’ disease were able to tolerate the second vaccine dose. The follow-up progress was described in only one patient, who was diagnosed with new onset Graves’ disease shortly after the first mRNA vaccine dose and received the second dose of vaccine 71 days later with a documented thyroid function test showing no further exacerbation (11).
Apart from Graves’ disease, subacute thyroiditis is a differential diagnosis to consider in thyrotoxic individuals. It is important to distinguish both entities as the management and course of disease is different. Based on recent reports of subacute thyroiditis cases occurring after receiving the SARS-CoV-2 vaccine (10, 13-14, 21-37), majority of these patients became symptomatic within short days to weeks with neck pain being the chief complaint. The TRAb concentrations were normal in all patients upon presentation, while the erythrocyte sedimentation rate was elevated in all cases. The diagnosis of subacute thyroiditis was supported by thyroid scintigraphy findings of reduced tracer uptake. Majority of these patients responded well to a combination of non-steroidal anti-inflammatory drug, glucocorticoid and beta-blocker with full resolution of symptoms and normalization of thyroid function shortly after initiation of treatment.

Discussion:

The RNA-based SARS-CoV-2 vaccines have been extensively administered since its approval. We report an extensive case series with temporal sequence of new-onset or relapse of Graves’ disease potentially triggered by exposure to the SARS-CoV-2 mRNA vaccines. In our case series, we observed that the exacerbation of hyperthyroidism can occur after the first or subsequent doses of the vaccine. Importantly, all the patients were able to tolerate a subsequent booster dose of SARS-CoV-2 mRNA vaccine without further exacerbation of hyperthyroidism.

Whether thyroid autoimmunity may develop among individuals exposed to other types of SARS-CoV-2 vaccines (e.g. DNA-based) is currently unclear. In the literature, only a handful
of similar precipitation of Graves’ disease and subacute thyroiditis has been reported after influenza or H1N1 vaccination (38 – 41). These cases may be under reported as clinicians may not associate the condition with the vaccination.

While in the above cases, the temporal sequence suggests that thyrotoxicosis may be related to the SARS-CoV-2 vaccination, there is currently no evidence to prove a causal relationship. The relationship can only be postulated to be at best as “probable”. The vaccination may serve as a precipitating agent. Using the analogy recently published in JCEM (42), the vaccination may at best be considered to be another rain cloud in the trajectory of Graves’ disease. In an individual with pre-existing Graves’ disease it may serve as a role of a sudden rain cloud which may disrupt the steady state and will need re-enforcement of an umbrella; while in a new onset Graves’ disease it may be a sudden rain cloud which disrupts the baseline latency of the autoimmune problem and precipitates a full blown disease (42). However, baseline predisposing factors would have been present in the individuals and the vaccine cannot be considered as a causative agent. Selenium supplementation and optimizing Vitamin D levels may be considered to minimize aberrant autoimmune reactions in patients known to have pre-existing autoimmune disorders (43).

There is a concern about the possible deleterious effect of the 2nd dose in patients who present after the first dose or booster doses. This limited series shows that – for Graves’ hyperthyroidism, they can go for a second dose without any significant problems if treatment is initiated before the vaccination and hyperthyroidism is controlled. These patients can be treated like we prepare patients for surgery and efforts need to be made to control free T4 and free T3 concentrations before the subsequent dose as much as possible.
Possible mechanisms by which these vaccines result in exacerbation of thyroid autoimmunity includes: 1. Direct activation of the ACE2 receptors on the thyroid gland (44); 2. Molecular mimicry with cross-reactivity with components of the SARS-CoV-2 mRNA vaccines encoding proteins that may cross-react with thyroid antigens (45); 3. When the SARS-CoV-2 mRNA vaccine carrying specific proteins that mimic thyroid antigens are presented to the antigen-presenting cells, the T and B lymphocytes become activated and trigger downstream immune signaling pathways (46), which could trigger Graves’ disease in predisposed individuals; 4. The induction of autoimmunity by vaccine adjuvants, resulting in the autoimmune/inflammatory syndrome (ASIA).

The differential activation of T and B lymphocytes plays a crucial role in the pathogenesis of Graves’ disease. Previously, Graves’ disease was thought to be predominantly driven by humoral cellular responses mediated by T-helper 2 (Th2) cells (47). However, recent evidence suggests that cell-mediated responses involving T-helper 1 (Th1) cells, characterized by interferon-gamma (IFN-γ), occur in the early phase of Graves’ disease. The T-cell repertoire then progressively shifts towards Th2 in the later course of the disease (48, 49). Cytokines, including IFN-γ and tumour necrosis factor-alpha, have synergistic effects in promoting the synthesis of Th1 associated chemokines, which may, in turn, perpetuate thyroidal inflammation (48). The robust Th1 cellular response, characterized by high IFN-γ levels, induced by the SARS-CoV-2 mRNA vaccine (50, 51) could be one of the possible mechanisms underpinning the unmasking of Graves’ disease in predisposed individuals or trigger relapse in a previously well-controlled individual with Graves’ disease.
Another possible mechanism mediating the development of Graves’ disease could be associated with the induction of autoimmunity by vaccine adjuvants, resulting in the autoimmune/inflammatory syndrome (ASIA). This syndrome has been reported with exposure to other vaccines, including influenza, hepatitis, and human papillomavirus, as well as vaccine adjuvants such as mineral oils and polyethylene glycol (PEG) (8). The RNA-based vaccines carrying modified viral proteins are delivered to the host cells via lipid nanoparticles adjuvants to increase the immunogenicity of the vaccine (52). As one of the lipid adjuvants is PEG, the exposure could potentially induce an exaggerated immune response and precipitate the development of thyroid autoimmunity (53). Despite attempts to describe the underlying mechanisms, ASIA remains poorly understood. Enhanced vigilance to identify more potential cases of ASIA, coupled with detailed evaluation of each case is crucial to further characterize this entity.

Conclusion

Our case series provide insight into the characteristics of individuals in whom Graves’ disease was triggered by SARS-CoV-2 vaccination. Most of the patients were able to go for a subsequent dose without any further exacerbations. With the rapid emergence of new SARS-CoV-2 variants, the need for regular booster vaccinations may become a possibility in the near future. We believe that the SARS-CoV-2 vaccinations or boosters should not be delayed given the clear protection against severe disease conferred by the vaccine. Increased awareness among endocrinologists and primary care physicians and patients is required for early identification of a relapse or new onset Graves’ disease. With timely diagnosis and prompt initiation of treatment, further doses of the SARS-CoV-2 vaccine can be safely administered and minimizes unnecessary delay in completing the vaccination schedule. Further epidemiological and mechanistic studies are required to elucidate the
possible associations between the SARS-CoV-2 vaccines and the development of thyroid autoimmunity.
Declaration of Interest: All authors state that they have no conflict of interest with regards to this manuscript.

Author contributions: CYJ, RD, conceptualized the study, recruited the participants, performed data analysis, data interpretation, literature review, wrote the manuscript and critically reviewed manuscript. AT, LHL conceptualized the study, recruited the participants, and critically reviewed the manuscript. All other authors contributed towards recruitment and critically reviewed the final manuscript.

Acknowledgements: We thank all the patients who participated in this study.

Funding: RD is supported in part by Ministry of Health, Clinician Scientist Award [MOH-000014]; NHG-LKC Clinician Scientist Fellowship. AWKT is supported by the NHG-LKC Clinician Scientist Fellowship.
References:

1. Covid-19 map. Johns Hopkins Coronavirus Resource Center. Accessed December 21, 2021, https://coronavirus.jhu.edu/map.html

2. World Health Organization (WHO). COVID. Accessed December 21, 2021, https://covid19.trackvaccines.org/agency/who/

3. World Health Organization (WHO). COVID19 Vaccine Tracker. Accessed December 21, 2021, https://covid19.trackvaccines.org/types-of-vaccines/

4. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosie OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301-316.

5. Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun. 2021 Dec;125:102738.

6. Lui DTW, Lee KK, Lee CH, Lee ACH, Hung IFN, Tan KCB. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review. Front Public Health. 2021;9:778964.

7. Sriphrapradang C, Shantavasinkul PC. Graves' disease following SARS-CoV-2 vaccination. Endocrine. 2021;74(3):473-474.

8. Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, Sánchez Valadez TI, Jara LJ. Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants. Thyroid. 2021;31(9):1436-1439.
9. Zettinig G, Krebs M. Two further cases of Graves' disease following SARS-Cov-2 vaccination. *J Endocrinol Invest*. Published online August 2021. doi:10.1007/s40618-021-01650-0

10. Pujol A, Gómez LA, Gallegos C, Nicolau J, Sanchís P, González-Freire M, López-González ÁA, Dotres K, Masmiquel L. Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV2 vaccination: from Graves' disease to silent thyroiditis. *J Endocrinol Invest*. Published online November 2021. doi: 10.1007/s40618-021-01707-0.

11. Yamamoto K, Mashiba T, Takano K, Suzuki T, Kami M, Takita M, Kusumi E, Mizuno Y, Hamaki T. A Case of Exacerbation of Subclinical Hyperthyroidism after First Administration of BNT162b2 mRNA COVID-19 Vaccine. *Vaccines (Basel)*. 2021;9(10):1108.

12. Weintraub MA, Ameer B, Sinha Gregory N. Graves' Disease Following the SARS-CoV-2 Vaccine: Case Series. *J Investig Med High Impact Case Rep*. 2021;9:2324709621106356.

13. Raven LM, McCormack AI, Greenfield JR. Letter to the Editor from Raven: Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine. *J Clin Endocrinol Metab*. Published online November 2021. doi: 10.1210/clinem/dgab822.

14. Lee KA, Kim YJ, Jin HY. Thyrotoxicosis after COVID-19 vaccination: seven case reports and a literature review. *Endocrine*. 2021;74(3):470-472. doi: 10.1007/s12020-021-02898-5.

15. di Filippo L, Castellino L, Giustina A. Occurrence and response to treatment of Graves' disease after COVID vaccination in two male patients. *Endocrine*. Published online November 2021. doi: 10.1007/s12020-021-02919-3.
16. Pierman G, Delgrange E, Jonas C. Recurrence of Graves' Disease (a Th1-type Cytokine Disease) Following SARS-CoV-2 mRNA Vaccine Administration: A Simple Coincidence? Eur J Case Rep Intern Med. 2021;8(9):002807.

17. Sriphrapradang C. Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves' disease. Endocrine. 2021;74(2):226-227.

18. Singapore Population. Department of Statistics Singapore. Accessed 23 December 2021, https://www.singstat.gov.sg/modules/infographics/population

19. COVID-19 Vaccination. Ministry of Health Singapore. Updated 21 December 2021. Accessed 23 December 2021, https://www.moh.gov.sg/covid-19/vaccination

20. Mammen JSR, Cappola AR. Autoimmune Thyroid Disease in Women. JAMA. 2021; 325(23):2392–2393.

21. Khan F, Brassill MJ. Subacute thyroiditis post-Pfizer-BioNTech mRNA vaccination for COVID-19. Endocrinol Diabetes Metab Case Rep. Published online December 2021. doi: 10.1530/EDM-21-0142.

22. Sözen M, Topaloğlu Ö, Çetinarslan B, Selek A, Cantürk Z, Gezer E, Köksalan D, Bayraktaroğlu T. COVID-19 mRNA vaccine may trigger subacute thyroiditis. Hum Vaccin Immunother. Published online December 2021. doi: 10.1080/21645515.2021.2013083.

23. İremli BG, Şendur SN, Ünlütürk U. Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Postvaccination ASIA Syndrome. J Clin Endocrinol Metab. 2021;106(9):2600-2605.
24. Siolos A, Gartzonika K, Tigas S. Thyroiditis following vaccination against COVID-19: Report of two cases and review of the literature. *Metabol Open*. 2021;12:100136. doi:10.1016/j.metop.2021.100136

25. Franquemont S, Galvez J. Subacute Thyroiditis After mRNA Vaccine for Covid-19. *J Endocr Soc*. 2021;5(Suppl 1):A956-A957. Published 2021 May 3. doi:10.1210/jendso/bvab048.1954

26. Soltanpoor P, Norouzi G. Subacute thyroiditis following COVID-19 vaccination. *Clin Case Rep*. 2021;9(10):e04812. Published online October 2021. doi:10.1002/ccr3.4812

27. Pandya M, Thota G, Wang X, Luo H. Thyroiditis after Coronavirus Disease 2019 (COVID-19) mRNA Vaccine: A Case Series. *AACE Clin Case Rep*. Published online December 2021. doi: 10.1016/j.aace.2021.12.002.

28. Chatzi S, Karampela A, Spiliopoulou C, Boutzios G. Subacute thyroiditis after SARS-CoV-2 vaccination: a report of two sisters and summary of the literature. *Hormones (Athens)*. Published online October 2021. doi: 10.1007/s42000-021-00332-z.

29. Bornemann C, Woyk K, Bouter C. Case Report: Two Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccination. *Front Med (Lausanne)*. 2021 Aug 24;8:737142.

30. Oyibo SO. Subacute Thyroiditis After Receiving the Adenovirus-Vectored Vaccine for Coronavirus Disease (COVID-19). *Cureus*. 2021 Jun 29;13(6):e16045.

31. Kyriacou A, Ioakim S, Syed AA. COVID-19 vaccination and a severe pain in the neck. *Eur J Intern Med*. 2021;94:95-96.

32. Plaza-Enriquez L, Khatiwada P, Sanchez-Valenzuela M, Sikha A. A Case Report of Subacute Thyroiditis following mRNA COVID-19 Vaccine. *Case Rep Endocrinol*. 2021 Nov;2021:8952048.
33. Patel KR, Cunnane ME, Deschler DG. SARS-CoV-2 vaccine-induced subacute thyroiditis. *Am J Otolaryngol*. 2022;43(1):103211.

34. Şahin Tekin M, Şaylisoys S, Yorulmaz G. Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report. *Hum Vaccin Immunother*. Published online July 2021. doi: 10.1080/21645515.2021.1947102.

35. Schimmel J, Alba EL, Chen A, Russell M, Srinath R. Letter to the Editor: Thyroiditis and Thyrotoxicosis After the SARS-CoV-2 mRNA Vaccine. *Thyroid*. 2021;31(9):1440.

36. Jeeyavudeen MS, Patrick AW, Gibb FW, Dover AR. COVID-19 vaccine-associated subacute thyroiditis: an unusual suspect for de Quervain's thyroiditis. *BMJ Case Rep.* 2021;14(11):e246425.

37. Saygılı ES, Karakılıc E. Subacute thyroiditis after inactive SARS-CoV-2 vaccine. *BMJ Case Rep.* 2021;14(10):e244711.

38. Hsiao JY, Hsin SC, Hsieh MC, Hsia PJ, Shin SJ. Subacute thyroiditis following influenza vaccine (Vaxigrip) in a young female. *Kaohsiung J Med Sci*. 2006;22(6):297-300.

39. Altay FA, Güz G, Altay M. Subacute thyroiditis following seasonal influenza vaccination. *Hum Vaccin Immunother*. 2016;12(4):1033-4.

40. Girgis CM, Russo RR, Benson K. Subacute thyroiditis following the H1N1 vaccine. *J Endocrinol Invest*. 2010;33(7):506.

41. Leiva S, Madrazo J, Podesta C. Narcolepsy with cataplexy and hyperthyroidism sudden appeared after H1N1 vaccination. *Sleep Sci*. 2018;11(1):34-36.

42. Rodien P. Graves' Disease in the Young: could we change the weather? *J Clin Endocrinol Metab*. Published online December 2021. doi: 10.1210/clinem/dgab909.
43. R. Dalan and B.O. Boehm. Micronutrient supplementation before COVID-19 vaccination can protect against adverse effects. *Clinical Nutrition ESPEN*, https://doi.org/10.1016/j.clnesp.2021.11.008.

44. Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngimateju ST, Villani L, Magri F, Latrofa F, Chiovato L. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. *J Endocrinol Invest*. 2021;44(5):1085-1090.

45. Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. *Front Immunol*. 2021;11:617089.

46. McIver B, Morris JC. The pathogenesis of Graves' disease. *Endocrinol Metab Clin North Am*. 1998;27(1):73-89.

47. Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves' disease, and thyroid-associated ophthalmopathy. *Thyroid*. 2008;18(9):953-8.

48. Ferrari SM, Ruffilli I, Elia G, Ragusa F, Paparo SR, Patrizio A, Mazzi V, Antonelli A, Fallahi P. Chemokines in hyperthyroidism. *J Clin Transl Endocrinol*. 2019;16:100196.

Erratum in: *J Clin Transl Endocrinol*. 2020;23:100246.

49. Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves' disease. *Immunol Res*. 2012;54(1-3):191-203.

50. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D, Eller AK, Grützner J, Boesler C, Rosenbaum C, Kühnle MC, Luxemburger U, Kemmer-Brück A, Langer D, Bexon M, Bolte S, Karikó K, Palanche T, Fischer B, Schultz A, Shi PY, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL,
Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Türeci Ö. COVID-19 vaccine BNT162b1 elicits human antibody and T_{H}1 T cell responses. *Nature*. 2020;586(7830):594-599. Erratum in: *Nature*. 2021;590(7844):E17.

51. Tan AT, Lim JM, Le Bert N, Kunasegaran K, Chia A, Qui MD, Tan N, Chia WN, de Alwis R, Ying D, Sim JX, Ooi EE, Wang LF, Chen MI, Young BE, Hsu LY, Low JG, Lye DC, Bertoletti A. Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. *J Clin Invest*. 2021;131(17):e152379.

52. Hou, X., Zaks, T., Langer, R. et al. Lipid nanoparticles for mRNA delivery. *Nat Rev Mater.* Published online August 2021. doi: 10.1038/s41578-021-00358-0.

53. Strategic Advisory Group of Experts (SAGE) on Immunization Working Group on COVID-19 Vaccines. Geneva: World Health Organization. mRNA vaccines against COVID-19: Pfizer-BioNTech COVID-19 vaccine BNT162b2. December 2020. Available online at: https://apps.who.int/iris/handle/10665/338096 (accessed December 23, 2021).
Table 1: Demographic, clinical and laboratory characteristics of our cohort of patients with Graves’ disease after exposure to SARS-CoV-2 mRNA vaccine

| Patient | Age | Sex | Ethnicity | New onset vs GD relapse | Time of symptom onset after vaccination | TFT at diagnosis/relapse | TRAb at diagnosis/relapse | Exacerbation of symptoms after second dose (if GD diagnosed/reapsed after 1st dose) | TFT pre 2nd dose (if GD diagnosed/reapsed after 1st dose) | TFT post 2nd dose (if GD diagnosed/reapsed after 1st dose) | Treatment given | Time to normal FT4 (days) | Time to normal FT3 (days) |
|---------|-----|-----|-----------|-------------------------|---------------------------------|----------------------|------------------------|--------------------------------------------------------|---------------------------------|--------------------------------------------------------|-----------------|----------------------|----------------------|
| 1       | 33/F | Yes | Chinese   | No                       | 7 days after 1st dose            | FT4 45 TSH 0.01        | No                     | FT4 14 TSH 0.01 (done after 1st dose)                  | No                               | FT4 8 TSH < 0.01 (done after 2nd dose)                  | Carbimazole 30mg OM and propranolol 20mg BD | 28                   | NA                   |
| 2       | 37/F | No  | Filipino  | No                       | 7 days after 1st dose            | FT4 60 TSH < 0.01      | No                     | FT4 38 TSH 0.32 (done after 1st dose)                  | No                               | FT4 8 TSH < 0.01 (done after 2nd dose)                  | Carbimazole 20mg OM and propranolol 10mg BD | 32 3                   | NA                   |
| No. | Age | Gender | Marital Status | New | 1st Dose | 2nd Dose | FT4 | TSH | TSH R | FT4 2nd Dose | TSH 2nd Dose | Change in Car and Prop | Notes |
|-----|-----|--------|----------------|-----|----------|----------|-----|-----|-------|--------------|--------------|------------------------|-------|
| 3   | 37/F| Filipino| No             | Yes | 21 days  | 72       | Not done | <0.01 | 11.2 | NA    | Carbamazepine | 20mg OM Propranolol | Yes        | 53 NA |
| 4   | 34/F| Malay   | Yes            | Yes | 26 days  | 68       | Not done | 0.01  | 23.8 | 32 No | Carbamazepine | 30mg OM Propranolol | Yes        | 58 58 |
| 5   | 33/F| Chinese | No             | Yes | 9 days   | 29       | Not done | <0.01 | 4.6  | NA    | Carbamazepine | 30mg OM Propranolol | Yes        | 64 NA |
| 6   | 43/F| Chinese | No             | Yes | 13 days  | 70       | >40    | 6.2   | NA   | NA    | Carbamazepine | 20mg OM Beta-blockade | Yes        | 29 57 |
| 7   | 59/M| Chinese | Yes            | Yes | 21 days  | 49       | Not done | 12.8  | NA   | NA    | Carbamazepine | Still elevated | Yes        | NA   |
| No | Age | Sex | Ethnicity | Relaps | Asymptomatic (TFT performed as part of routine follow-up) | FT4 | FT3 | TSH | Carbimazole | Beta-blockade | Notes |
|----|-----|-----|-----------|--------|---------------------------------------------------------|-----|-----|-----|-------------|--------------|-------|
| 8  | 74/F| Yes | Chinese   | No     | Asymptomatic (TFT performed after 2nd dose)              | FT4 | Not | 6.2 | NA          | NA           | Carbimazole 2.5mg daily Beta-blockade not required |
|    |     |     |           |        | FT4 14 TSH 0.02                                         |     |     |     | FT4 15 TSH 0.01 | FT4 14 TSH 0.01 | Carbimazole 5mg daily Beta-blockade not required |
| 9  | 25/F| Yes | Chinese   | No     | Asymptomatic (TFT performed after 2nd dose)             | FT4 | 6.3 | 2.9 | NA          | NA           | Carbimazole 5mg daily Beta-blockade not required |
|    |     |     |           |        | FT4 15 TSH 0.01                                         |     |     |     | FT4 15 TSH 1.41 | FT4 15 TSH 0.01 | Carbimazole 5mg daily Beta-blockade not required |
| 10 | 41/F| No  | Chinese   | Yes    | Asymptomatic (TFT done after 2nd dose)                 | FT4 | 3.9 | NA  | Not done   | Not done    | Carbimazole 20mg daily Beta-blockade not required |
|    |     |     |           |        | FT4 50 TSH < 0.01                                       |     |     |     | FT4 20 TSH 0.01 | FT4 20 TSH 0.01 | Carbimazole increase |
| 11 | 24/F| No  | Chinese   | Yes    | Asymptomatic (TFT done after 2nd dose)                 | FT4 | 2.4 | NA  | NA         | NA          | Carbimazole increase |
|    |     |     |           |        | FT4 20 TSH 0.01                                        |     |     |     | FT4 20 TSH 0.01 | FT4 20 TSH 0.01 | Carbimazole increase |
Abbreviations: FHx – family history; TED: thyroid eye disease; GD – Graves’ Disease; TFT – thyroid function test; FT4 – free thyroxine (pmol) (RI 8–16); FT3 – free triiodothyronine (pmol) (RI 3.5 – 6.0); TSH – thyroid stimulating hormone (mIU/L) (RI 0.45 – 4.5); TRAb – TSH receptor antibody (IU/L) (RI < 1)
Table 2: Summary of demographic, clinical and laboratory characteristics of the existing 21 cases of Graves’ disease post SARS-CoV-2 vaccination in the literature

| Reference | Sex/Age (years) | Country | Vaccine | Co-morbidities | New vs. relapse of GD | Days of symptom onset |
|-----------|----------------|---------|---------|----------------|----------------------|----------------------|
| 5         | Male, 52       | Italy   | mRNA    | Diabetes mellitus, vitiligo | New | 28 days after 2nd dose |
| 6         | Female, 40     | Hong Kong | mRNA | Hypothyroidism | Switch to hyperthyroidism | 38 days after 2nd dose |
| 7         | Male, 70       | Thailand | Viral vector | Not reported | New | 2 days after 2nd dose |
| 8         | Female, 40     | Mexico   | mRNA | past COVID infection | New | 2 days after receiving a dose |
| 8         | Female, 28     | Mexico   | mRNA | None | New | 3 days after receiving a dose |
| 9         | Male, 46       | Austria  | mRNA | None | New | 15 days from 1st dose |
| 10        | Female, 38     | Spain    | mRNA | Schizophrenia | New | 12 days from 1st dose |
| 11        | Female, 64     | Japan    | mRNA | Colorectal cancer, diabetes mellitus, obesity | New | 4 days from 1st dose |
| 12        | Female, 38     | USA      | mRNA | Not reported | New | 5 days after 1st dose |
| 12        | Female, 63     | USA      | mRNA | Not reported | New | 7 days after 1st dose |
| 12        | Male, 30       | USA      | mRNA | Not reported | New | 28 days after |
| No. | Age | Gender | Location | Vaccine Type | Disease Status | Symptoms | Time After Dose |
|-----|-----|--------|----------|--------------|---------------|----------|----------------|
| 13  | 35  | Female | Australia | Viral vector | New           |          | 5 days after 1st dose |
| 14  | 46  | Female | Korea    | Viral vector | New           |          | 1 day after 1st dose |
| 14  | 73  | Female | Korea    | Viral vector | New           |          | 14 days after 2nd dose |
| 14  | 34  | Male   | Korea    | Viral vector | New           |          | 14 days after dose |
| 15  | 32  | Male   | Italy    | Viral vector | New           |          | 10 days after 2nd dose |
| 15  | 35  | Male   | Italy    | Viral vector | New           |          | 5 days after 1st dose |
| 16  | 34  | Female | Belgium  | mRNA        | GD in remission | Relapse | 10 days from 1st dose; symptoms worsened after 2nd dose |
| 9   | 71  | Female | Austria  | mRNA        | GD in remission | Relapse | Approximately 1 month from 2nd dose |
| 17  | 30  | Female | Thailand | Viral vector | GD in remission | Worsening Graves' disease | 4 days after booster dose |
| 14  | 39  | Male   | Korea    | Viral vector | Not reported | Subacute thyroiditis & Graves' | 14 days after dose |
Abbreviations: GD – Graves’ disease; TFT – thyroid function test; FT4 – free thyroxine (pmol) (all values converted to pmol/L); TSH – thyroid stimulating hormone (mIU/L); TRAb – TSH receptor antibody (IU/L or IU/ml); TSI – thyroid stimulating immunoglobulin (% or IU/L)